2015 Annual Meeting of the American Association for the Study of Liver Diseases*

Download All
November 13-17, 2015; San Francisco, California
CCO’s Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases includes Capsule Summaries, reviews by expert faculty on key studies highlighted at the conference and a downloadable slide set.

Clinical Impact of New Data From AASLD 2015

Capsules

One-pill, once-daily combination superior to sofosbuvir plus ribavirin, with no cases of virologic failure in open-label phase III trial.

Released: November 19, 2015

Use of shorter 12-week treatment regimen highly effective in patients with F3 disease.

Released: November 17, 2015

Similar SVR24 rates in white patients vs black patients; SVR12 rate not affected by baseline RAVs in patients with genotype 1a HCV infection.

Released: November 20, 2015

Low rates of discontinuation due to AEs, treatment-related serious AEs, and/or grade 3 and 4 lab abnormalities in this interim analysis.

Released: November 20, 2015

Analysis finds 8-week regimen is underused, despite being highly effective in qualifying patients.

Released: November 17, 2015

High SVR rates maintained across patient subgroups, including cirrhotic and treatment-experienced patients; adverse event rates similar to placebo.

Released: November 18, 2015

Both 12-week and 16-week regimens of daclatasvir plus sofosbuvir plus ribavirin were well tolerated, even in cirrhotic, treatment-experienced patients usually considered difficult to treat.

Released: November 20, 2015

No relapse in noncirrhotic patients regardless of inclusion of ribavirin; no relapse in cirrhotic patients with 16 weeks of treatment including ribavirin.

Released: November 19, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings